Akili Interactive Labs

The company plans to use the new funds to expand its therapeutics beyond ADHD. 

The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.

In response to recent COVID-19 guidance, the company is releasing its video game-like treatment to qualifying families at no cost, and without explicitly requiring a doctor's prescription.

The large, multi-site investigation described clear improvement in objective symptoms of pediatric attention deficit, but was a bit muddier when describing subjective measures and long-term efficacy.

Topline data released today by the digital therapeutics company also suggest that its FDA approval-pending treatment continued to deliver benefits with continued use.

The study, which was presented at the Meeting of the American College of Neuropsychopharmacology yesterday, found that patients using the technology improved their sustained attention compared to those in the control group. 

Digital therapeutic stakeholders came together at this week's DTx East conference to discuss the state of digital health investment, developing successful business models, the need for robust data and more.

Stakeholders at today's DTx East event in Boston discuss digital therapeutic risk assessment and management. 

Of note, the deal specifies that Akili will still control the rollout and support of its video game-like therapy through a yet-to-be-seen digital distribution platform.

At CES 2019, the digital therapeutic company's CEO and cofounder described work on an independent prescription, procurement and support platform specific to digital medicines.